Making COVID-19 vaccines accessible for all
The European Union is committed to ensuring universal access to safe and effective COVID-19 vaccines as part of a lasting solution to the pandemic. Global collaboration through COVAX is best placed to help us reach this goal.
COVAX Facility explained
COVAX is the vaccines pillar of the Access to COVID-19 Tools Accelerator, which we launched together with the World Health Organization (WHO) and France in April 2020. It is coordinated by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO alongside key delivery partner UNICEF.
COVAX includes a mechanism – the Gavi COVAX Advance Market Commitment – that enables low- and middle-income economies to access donor-funded doses of vaccines. Team Europe – the European Union with its Member States and the European Investment Bank – is one of its leading contributors with over €2.47 billion pledged so far.
Vaccines delivery roll-out
The first deliveries of COVID-19 vaccines through COVAX started on 24 February 2021. This is the largest, most rapid and complex global roll-out of vaccines in history. By the end of 2021, at least 1.3 billion COVAX doses should reach the 92 economies eligible for support through the AMC.
The EU will also support partners with vaccination strategies and the distribution of supplies, and explore boosting the local manufacturing capacity of vaccines.